Surfactant protein c is an essential constituent for mucosal adjuvanticity of surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity

Vaccine

Volumn 29, Issue 33, 2011, Pages 5368-5378

  Mizuno, Dai ^a   Kimoto, Takashi ^a   Takei, Tsunetomo ^a   Fukuta, Akiho ^a   Shinahara, Wakako ^a   Takahashi, Etsuhisa ^a   Yano, Mihiro ^a   Kido, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antigen vehicle; Dendritic cells; Mucosal adjuvant; Nasal vaccination; Pulmonary surfactant

Indexed keywords

CD86 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ VACCINE SURFACTANT TA COMPLEX; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SURFACTANT PROTEIN C; SURFACTANT TA; UNCLASSIFIED DRUG;

ADJUVANTICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE CAVITY; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, CD86; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDES, CYCLIC; RODENT DISEASES; VACCINES, SUBUNIT;

EID: 79960366326     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.090     Document Type: Article

References (37)

1. Demicheli V., Jefferson T., Rivetti D., Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000, 18:957-1030.
2. Wilde J.A., McMillan J.A., Serwint J., Butta J., O'Riordan M.A., Steinhoff M.C. Effectiveness of influenza vaccine in health care professionals: A randomized trial. JAMA 1999, 281:908-913.
3. Bridges C.B., Thompson W.W., Meltzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000, 284:1655-1663.
4. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: A systematic review. Lancet 2005, 366:1165-1174.
5. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild type virus. J Clin Microbiol 1986, 24:157-160.
6. Tamura S.I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 1992, 22:477-481.
7. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53.
8. CDC Notice to readers: Expansion of use of live, attenuated influenza vaccine (FluMist) to children age 2-4 years and other FluMist changes for the 2007-2008 influenza seasons. MNWR 2007, 56:1217-1219.
9. Belshe R.B., Nichol K.L., Black S.B., Shinefield H., Cordova J., Walker R., et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population age 5-49 years. Clin Infect Dis 2004, 39:920-927.
10. McCarthy M.W., Kockler D.R. Trivalent intranasal influenza vaccine, live. Ann Pharmacother 2004, 38:2086-2093.
11. Nishino M., Mizuno D., Kimoto T., Shinahara W., Fukuta A., Takei T., et al. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. Vaccine 2009, 27:5620-5627.
12. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 2001, 51:21-42.
13. Durrer P., Glück U., Spyr C., Lang A.B., Zurbriggen R., Herzog C., et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 2003, 21:4328-4334.
14. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350:896-903.
15. Mizuno D., Ide-Kurihara M., Ichinomiya T., Kubo I., Kido H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J Immunol 2006, 176:1122-1130.
16. Schmitz G., Müller G. Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. J Lipid Res 1991, 32:1539-1570.
17. Balis J.U., Paterson J.F., Lundh J.M., Haller E.M., Shelley S.A., Montgomery M.R. Ozone stress initiates acute perturbations of secreted surfactant membranes. Am J Pathol 1991, 138:847-857.
18. Ochs M., Johnen G., Müller K.-M., Wahlers T., Hawgood S., Richter J., et al. Intracellular and intraalveolar location of surfactant protein A (SP-A) in the parenchymal region of the human lung. Am J Respir Cell Mol Biol 2002, 26:91-98.
19. Gurel O., Ikegami M., Chroneos Z.C., Jobe A.H. Macrophage and type II cell catabolism of SP-A and saturated phosphatidylcholine in mouse lungs. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1266-L1272.
20. Wright J.R., Clements J.A. Metabolism and turnover of lung surfactant. Am Rev Respir Dis 1987, 136:426-444.
21. Tanaka Y., Takei T., Aiba T., Masuda K., Kiuchi A., Fujiwara T. Development of synthetic lung surfactants. J Lipid Res 1986, 27:475-485.
22. Tanaka Y., Takei T. Lung surfactants I. Comparison of surfactants prepared from lungs of calf, ox, dog and rabbit. Chem Pharm Bull (Tokyo) 1983, 31:4091-4099.
23. Yoshida M., Ikegami M., Reed J.A., Chroneos Z.C., Whitsett J.A. GM-CSF regulates protein and lipid catabolism by alveolar macrophages. Am J Physiol Lung. Cell Mol Physiol 2001, 280:L379-L386.
24. Oosterlaken-Dijksterhuis M.A., Haagsman H.P., van Golde L.M., Demel R.A. Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C. Biochemistry 1991, 30:8276-8281.
25. Curstedt T., Jörnvall H., Robertson B. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant. Characterisation and biophysical analysis. Eur J Biochem 1987, 168:255-262.
26. Lutz M.B., Kuktsch N., Ogilvie A.L., Roßner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
27. Asanuma H., Thompson A.H., Iwasaki T., Sato Y., Inaba Y., Aizawa C., et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods 1997, 202:123-131.
28. Kawamoto T., Shimizu M. A method for preparing 2- to 50-micron-thick fresh-frozen sections of large samples and undecalcified hard tissues. Histochem Cell Biol 2000, 113:331-339.
29. Mizuno D., Tanaka E., Tanno K., Misawa S. Chlorzoxazone: A probe drug whose metabolism can be used to monitor toluene exposure in rats. Arch Toxicol 2000, 74:139-144.
30. Wang S., Le T.Q., Kurihara N., Chida J., Cisse Y., Yano M., et al. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 2010, 201:991-1001.
31. Knowles M.R., Boucher R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002, 109:571-577.
32. Rubin B.R. Physiology of airway mucus clearance. Respir Care 2002, 47:761-768.
33. Nochi T., Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des 2006, 12:4203-4213.
34. Poelma D.L., Zimmermann L.J., van Cappellen W.A., Haitsma J.J., Lachmann B., van Iwaarden J.F. Distinct effects of SP-B and SP-C on the uptake of surfactant-like liposomes by alveolar cells in vivo and in vitro. Am J Physiol Lung Cell Mol Physiol 2004, 287:L1056-L1065.
35. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Mehta A., Vyas S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26:2225-2233.
36. Hattori Y., Kawakami S., Suzuki S., Yamashita F., Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun 2004, 317:992-999.
37. Bu J., Song Y., Rompatoa G., Burgess D.J., Garmendia A.E. Co-delivery of IL-2 or liposomes augment the responses of mice to a DNA vaccine for pseudorabies virus IE180. Comp Immunol Microbiol Infect Dis 2003, 26:175-187.